Trial Profile
A Single Arm, Open-label Phase 3b Study to Describe the Safety and Tolerability of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Ivosidenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Registrational
- Sponsors Servier
- 09 Dec 2023 According to Servier media release, data from the study were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition.
- 13 Jul 2023 Status changed from not yet recruiting to recruiting.
- 20 Jun 2023 New trial record